Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
valuation ratios | |
---|---|
pe ratio | 17.10 |
peg ratio | 0.48 |
price to book ratio | 2.16 |
price to sales ratio | 5.31 |
enterprise value multiple | 15.26 |
price fair value | 2.16 |
profitability ratios | |
---|---|
gross profit margin | 84.47% |
operating profit margin | 28.32% |
pretax profit margin | 33.66% |
net profit margin | 31.07% |
return on assets | 11.69% |
return on equity | 14.77% |
return on capital employed | 10.89% |
liquidity ratio | |
---|---|
current ratio | 33.45 |
quick ratio | 29.66 |
cash ratio | 0.00 |
efficiency ratio | |
---|---|
days of inventory outstanding | 510.98 |
operating cycle | 670.63 |
days of payables outstanding | 130.67 |
cash conversion cycle | 539.96 |
receivables turnover | 2.29 |
payables turnover | 2.79 |
inventory turnover | 0.71 |
debt and solvency ratios | |
---|---|
debt ratio | 0.05 |
debt equity ratio | 0.06 |
long term debt to capitalization | 0.05 |
total debt to capitalization | 0.05 |
interest coverage | 72.86 |
cash flow to debt ratio | 2.23 |
cash flow ratios | |
---|---|
free cash flow per share | 33.43 |
cash per share | 166.47 |
operating cash flow per share | 41.08 |
free cash flow operating cash flow ratio | 0.81 |
cash flow coverage ratios | 2.23 |
short term coverage ratios | 0.00 |
capital expenditure coverage ratio | 5.37 |
Frequently Asked Questions
Regeneron Pharmaceuticals, Inc. (REGN) published its most recent earnings results on 05-02-2025.
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s trailing twelve months ROE is 14.77%.
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Regeneron Pharmaceuticals, Inc. (REGN) currently has a ROA of 11.69%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
REGN reported a profit margin of 31.07% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
Apple's current ratio, which measures its ability to pay short-term obligations, was 33.45 in the most recent quarter. The quick ratio stood at 29.66, with a Debt/Eq ratio of 0.06.